Combining a histone deacetylase inhibitor drug with immunotherapy agents has been deemed safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial.
from Latest Science News -- ScienceDaily https://ift.tt/3geELbz
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment